KORONIS PHARMACEUTICALS INC has a total of 24 patent applications. Its first patent ever was published in 2002. It filed its patents most often in United States, Canada and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are GALECTIN SCIENCES LLC, ARMARON BIO PTY LTD and UNIV NORTH CAROLINA AT WILMING.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | Canada | 4 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | Australia | 2 | |
#5 | WIPO (World Intellectual Property Organization) | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations | |
#4 | Sugars | |
#5 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Gall Alexander | 23 |
#2 | Daifuku Richard | 23 |
#3 | Sergueev Dmitri | 16 |
#4 | Li Ling | 7 |
#5 | Harris Kevin | 6 |
#6 | Sologub Dina | 6 |
#7 | Partridge John | 1 |
#8 | Fromhold Mark | 1 |
Publication | Filing date | Title |
---|---|---|
WO2013036846A2 | N4 derivatives of deoxycytidine prodrugs | |
US2008249097A1 | Prodrugs of heteroaryl compounds | |
US2010279968A1 | Mutagenic Nucleoside Analogs for the Treatment of Viral Disease | |
US2007207973A1 | 1,3,5-Triazines for Treatment of Viral Diseases | |
US2008033172A1 | Mutagenic Heterocycles | |
US2005014752A1 | Prodrugs of heteroaryl compounds | |
US2004127436A1 | 1,3,5-triazines for treatment of viral diseases | |
WO03018030A1 | Mutagenic nucleoside analogs for the treatment of viral disease |